ASX:HLS Healius (HLS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Healius Stock (ASX:HLS) 30 days 90 days 365 days Advanced Chart Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Healius alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2.33 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield4.46%Price TargetN/AConsensus RatingN/A Company OverviewHealius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.Read More… Receive HLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Healius and its competitors with MarketBeat's FREE daily newsletter. Email Address HLS Stock News HeadlinesHealius Limited Announces Director Departure and ShareholdingsDecember 1, 2024 | tipranks.comHealius Limited Announces Board ChangesNovember 28, 2024 | tipranks.comCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.December 24, 2024 | Brownstone Research (Ad)Healius Limited Director Increases ShareholdingNovember 27, 2024 | tipranks.comHealius Director Increases Stake with New Share AcquisitionNovember 25, 2024 | tipranks.comHealius Limited Gains New Major Shareholder with SpheriaNovember 18, 2024 | tipranks.comHealius in management shake-up after CEO exitMarch 28, 2024 | afr.comMaking excuses for weak margins has ended: Healius CEOMarch 17, 2024 | afr.comSee More Headlines HLS Stock Analysis - Frequently Asked Questions How were Healius' earnings last quarter? Healius Limited (ASX:HLS) posted its quarterly earnings data on Friday, February, 15th. The company reported $0.04 EPS for the quarter, missing analysts' consensus estimates of $0.09 by $0.06. Healius had a negative net margin of 36.98% and a negative trailing twelve-month return on equity of 49.94%. What other stocks do shareholders of Healius own? Based on aggregate information from My MarketBeat watchlists, some other companies that Healius investors own include bluebird bio (BLUE), Argonaut Gold (AR), Athene (ATH), BELLUS Health (BLU), Esperion Therapeutics (ESPR), Fortress Biotech (FBIO) and Forte Biosciences (FBRX). Company Calendar Last Earnings2/15/2019Today12/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolASX:HLS CUSIPN/A CIKN/A Webwww.primaryhealthcare.com.au Phone61 2 9432 9400FaxN/AEmployees10,500Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-0.94Net Income$-636,000,000.00 Net Margins-36.98% Pretax MarginN/A Return on Equity-49.94% Return on Assets1.23% Debt Debt-to-Equity Ratio153.54 Current Ratio0.50 Quick Ratio0.47 Sales & Book Value Annual Sales$1.75 billion Price / Sales0.00 Cash FlowN/A Price / Cash Flow12.26 Book ValueA$1.43 per share Price / BookN/AMiscellaneous Outstanding Shares726,130,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.73 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (ASX:HLS) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredWall St. Icon: “If you wait on this, it will already be too late”If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this ...Crypto 101 Media | SponsoredTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Healius Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Healius With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.